Morten Graugaard Døssing

Partner at Novo Holdings

Speaker

Morten joined Novo Holdings in 2016 and serves as Partner in the company creation team of Seed Investments where he leads new company formation. He serves on the Board of Avilex Pharma, NMD Pharma, and Muna Therapeutics. In addition he is the executive chair of Orbis Medicines and is heading up the Novo SeedLab which is Novo Holdings’ venture creation lab that helps accelerate company creation. Morten was founding investor of Syndesi Therapeutics that was sold to AbbVie for up to USD 1 Bn.

Prior to joining Novo, Morten was Director of Corporate Development at H. Lundbeck A/S where he was involved in M&A, corporate strategy, BD&L, portfolio management and equity investments. While at Lundbeck Morten successfully led the acquisition of orphan neurology company Chelsea Therapeutics for 658 USD m and was involved in a range of other deals including the 1.8 USD Bn alliance with Otsuka Pharmaceuticals as well as equity investments and spinouts. Before Lundbeck, Morten worked in technology transfer as well as a the life science consulting practice.

Morten holds an MSc in Human Biology from the University of Copenhagen.